291 related articles for article (PubMed ID: 33971270)
41. Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine.
Narayana N; Cox S; Shaltiel S; Taylor SS; Xuong N
Biochemistry; 1997 Apr; 36(15):4438-48. PubMed ID: 9109651
[TBL] [Abstract][Full Text] [Related]
42. Ca
Fusi F; Trezza A; Spiga O; Sgaragli G; Bova S
Biochem Pharmacol; 2017 Sep; 140():53-63. PubMed ID: 28583845
[TBL] [Abstract][Full Text] [Related]
43. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
44. Designing of kinase hinge binders: A medicinal chemistry perspective.
Sharma V; Gupta M
Chem Biol Drug Des; 2022 Dec; 100(6):968-980. PubMed ID: 35112799
[TBL] [Abstract][Full Text] [Related]
45. Evolutionary variation and adaptation in a conserved protein kinase allosteric network: implications for inhibitor design.
Oruganty K; Kannan N
Biochim Biophys Acta; 2013 Jul; 1834(7):1322-9. PubMed ID: 23499783
[TBL] [Abstract][Full Text] [Related]
46. Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Cheung L; Yu DM; Neiron Z; Failes TW; Arndt GM; Fletcher JI
Biochem Pharmacol; 2015 Feb; 93(3):380-8. PubMed ID: 25462817
[TBL] [Abstract][Full Text] [Related]
47. The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2.
Gu R; Hibbs DE; Ong JA; Edwards RJ; Murray M
Biochem Pharmacol; 2014 Mar; 88(2):245-52. PubMed ID: 24462920
[TBL] [Abstract][Full Text] [Related]
48. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
49. Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.
Vahedi S; Chufan EE; Ambudkar SV
Biochem Pharmacol; 2017 Nov; 143():53-64. PubMed ID: 28728917
[TBL] [Abstract][Full Text] [Related]
50. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
51. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
52. Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.
Das D; Hong J
Mini Rev Med Chem; 2020; 20(17):1732-1753. PubMed ID: 32400331
[TBL] [Abstract][Full Text] [Related]
53. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
Chufan EE; Kapoor K; Ambudkar SV
Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
[TBL] [Abstract][Full Text] [Related]
54. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Dong RF; Zhu ML; Liu MM; Xu YT; Yuan LL; Bian J; Xia YZ; Kong LY
Pharmacol Res; 2021 May; 167():105583. PubMed ID: 33775864
[TBL] [Abstract][Full Text] [Related]
55. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
[TBL] [Abstract][Full Text] [Related]
56. Kinase hinge binding scaffolds and their hydrogen bond patterns.
Xing L; Klug-Mcleod J; Rai B; Lunney EA
Bioorg Med Chem; 2015 Oct; 23(19):6520-7. PubMed ID: 26358279
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole.
Beck KR; Bächler M; Vuorinen A; Wagner S; Akram M; Griesser U; Temml V; Klusonova P; Yamaguchi H; Schuster D; Odermatt A
Biochem Pharmacol; 2017 Apr; 130():93-103. PubMed ID: 28131847
[TBL] [Abstract][Full Text] [Related]
58. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.
Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA
Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391
[TBL] [Abstract][Full Text] [Related]
59. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
Ai X; Shen S; Shen L; Lu S
Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
[TBL] [Abstract][Full Text] [Related]
60. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Sampson A; Peterson BG; Tan KW; Iram SH
Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
